Regentis Biomaterials (RGNT) Stock Price, News & Analysis

Company Overview

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.

Key Stats

• Today's Range: $3.95 to $4.19
• 50-Day Range: $1.28 to $9.40
• 52-Week Range: $1.23 to $15.50
• Volume: 169,962 shs
• Average Volume: 16.50 million shs
• Market Capitalization: $21.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Regentis Biomaterials Stock Analysis - MarketRank™

Regentis Biomaterials scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Regentis Biomaterials has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Regentis Biomaterials has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

79.81% of the float of Regentis Biomaterials has been sold short.

Short Interest Ratio / Days to Cover

Regentis Biomaterials has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regentis Biomaterials has recently increased by 3,584.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regentis Biomaterials does not currently pay a dividend.

Dividend Growth

Regentis Biomaterials does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Regentis Biomaterials this week, compared to 1 article on an average week.

Search Interest

9 people have searched for RGNT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regentis Biomaterials insiders have not sold or bought any company stock.

Percentage Held by Insiders

77.20% of the stock of Regentis Biomaterials is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Regentis Biomaterials has minimal institutional ownership at this time.

Company Calendar

• Today: 6/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:RGNT
• CIK: 1912966
• Web: www.regentis.co.il
• Phone: 972-9960-1917
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.65
• Quick Ratio: 2.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.92 per share
• Price / Book: 4.51

Miscellaneous

• Outstanding Shares: 5,180,000
• Free Float: 1,181,000
• Market Cap: $21.50 million
• Optionable: N/A
• Beta: N/A